BioCryst Pharmaceuticals
BCRX
294 hedge funds and large institutions have $1.77B invested in BioCryst Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 114 increasing their positions, 84 reducing their positions, and 30 closing their positions.
95% more call options, than puts
Call options by funds: $12.7M | Put options by funds: $6.52M
73% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 30
36% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 84
34% more capital invested
Capital invested by funds: $1.32B → $1.77B (+$450M)
10.6% more ownership
Funds ownership: 83.63% → 94.23% (+11%)
7% more funds holding
Funds holding: 274 → 294 (+20)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$38M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$33.6M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$29.9M |
| 4 |
Morgan Stanley
New York
|
+$28.2M |
| 5 |
D.E. Shaw & Co
New York
|
+$26.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$39.1M |
| 2 |
CP
Caligan Partners
New York
|
-$23M |
| 3 |
Millennium Management
New York
|
-$17.8M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$15.3M |
| 5 |
Alkeon Capital Management
New York
|
-$14M |
BCRX Hedge Fund Activity: Q2 2025 in Review
294 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2025, worth a combined $1.77B — up 34% from $1.32B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new BCRX positions and 30 closed out — a net gain of 22 holders — while 114 added to existing stakes and 84 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $38M. The largest seller was Avoro Capital Advisors, cutting an estimated $39.1M.
- 294 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2025, up from 274 in Q1 2025.
- Funds reported $1.77B of BioCryst Pharmaceuticals stock for Q2 2025, up 34% quarter-over-quarter.
- 52 funds opened new BioCryst Pharmaceuticals positions in Q2 2025 and 30 closed out, a net change of +22 holders.
- The largest BioCryst Pharmaceuticals buyer in Q2 2025 was Arrowstreet Capital, an estimated $38M added.
- The largest BioCryst Pharmaceuticals seller in Q2 2025 was Avoro Capital Advisors, an estimated $39.1M sold.
Based on aggregated 13F filings for Q2 2025.